Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax with reduced intensive chemotherapy in AML and high-risk MDS
NCT06050941Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete Remission at 6 weeks. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06050941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050941.